On the public citation graph
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
0 signed · 1438 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/(sici)1097-0142(20000415)88:8<1964::aid-cncr27>3.0.co;2-1openalex-snapshot
Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1002/1097-0142(197608)38:2<672::aid-cncr2820380208>3.0.co;2-copenalex-snapshot
Remission induction in adult acute lymphocytic leukemia. Use of vincristine and prednisone alone
inferredcites →https://doi.org/10.1002/ajh.23778openalex-snapshot
A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1002/ajh.24419openalex-snapshot
Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen
inferredcites →https://doi.org/10.1002/cncr.11664openalex-snapshot
The biology and therapy of adult acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1002/cncr.23666openalex-snapshot
Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors
inferredcites →https://doi.org/10.1002/cncr.23919openalex-snapshot
Outcome of adults with acute lymphocytic leukemia after second salvage therapy
inferredcites →https://doi.org/10.1002/cncr.28136openalex-snapshot
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
inferredcites →https://doi.org/10.1002/cncr.29383openalex-snapshot
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1002/cncr.29646openalex-snapshot
Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with P hiladelphia chromosome–positive acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1002/cncr.30231openalex-snapshot
Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis
inferredcites →https://doi.org/10.1002/mpo.2950190411openalex-snapshot
Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia
inferredcites →https://doi.org/10.1002/pbc.25410openalex-snapshot
Characterization of CD22 expression in acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1007/978-1-62703-260-5_12openalex-snapshot
Nonviral RNA Transfection to Transiently Modify T Cells with Chimeric Antigen Receptors for Adoptive Therapy
inferredcites →https://doi.org/10.1007/bf00686263openalex-snapshot
Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1007/s00280-005-0135-zopenalex-snapshot
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
inferredcites →https://doi.org/10.1016/j.ccr.2012.06.005openalex-snapshot
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1016/j.clml.2015.04.006openalex-snapshot
Inotuzumab Ozogamicin (IO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) as Frontline Therapy for Older Patients (pts) and as Salvage Therapy for Adult with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
inferredcites →https://doi.org/10.1016/j.clml.2015.12.004openalex-snapshot
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1016/j.coi.2012.08.007openalex-snapshot
Genetic modification of lymphocytes by retrovirus-based vectors
inferredcites →https://doi.org/10.1016/j.critrevonc.2011.01.014openalex-snapshot
Treatment of acute lymphoblastic leukemia in adults
inferredcites →https://doi.org/10.1016/j.mayocp.2016.09.010openalex-snapshot
Adult Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1016/j.pharmthera.2012.07.013openalex-snapshot
Blinatumomab: A historical perspective
inferredcites →https://doi.org/10.1016/s0140-6736(14)61403-3openalex-snapshot
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
inferredcites →https://doi.org/10.1016/s0165-4608(96)00336-6openalex-snapshot
Bloom's syndrome. XX. The first 100 cancers
inferredcites →https://doi.org/10.1016/s0301-472x(03)00231-5openalex-snapshot
Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: A 15-year experience
inferredcites →https://doi.org/10.1016/s1470-2045(11)70386-2openalex-snapshot
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
inferredcites →https://doi.org/10.1016/s1470-2045(14)71170-2openalex-snapshot
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
inferredcites →https://doi.org/10.1016/s1658-3876(08)50058-6openalex-snapshot
Expression of CD66c and CD25 in acute lymphoblastic leukemia as a predictor of the presence of BCR/ABL rearrangement
inferredcites →https://doi.org/10.1017/cbo9780511471001.004openalex-snapshot
Epidemiology and etiology
inferredcites →https://doi.org/10.1021/jm060319fopenalex-snapshot
Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer
inferredcites →https://doi.org/10.1038/leu.2008.303openalex-snapshot
Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases
inferredcites →https://doi.org/10.1038/leu.2009.223openalex-snapshot
Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways
inferredcites →https://doi.org/10.1038/leu.2009.58openalex-snapshot
Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1038/nature05690openalex-snapshot
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
inferredcites →https://doi.org/10.1038/ng.2532openalex-snapshot
The genomic landscape of hypodiploid acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1038/ng.469openalex-snapshot
Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1038/sj.leu.2404824openalex-snapshot
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
inferredcites →https://doi.org/10.1038/srep17943openalex-snapshot
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
inferredcites →https://doi.org/10.1046/j.1365-2141.1997.1792996.xopenalex-snapshot
A prospective study of minimal residual disease in childhood B‐lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse
inferredcites →https://doi.org/10.1053/j.seminhematol.2008.09.001openalex-snapshot
Minimal Residual Disease in Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1056/nejmoa1306494openalex-snapshot
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
inferredcites →https://doi.org/10.1056/nejmoa1313984openalex-snapshot
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
inferredcites →https://doi.org/10.1056/nejmoa1403088openalex-snapshot
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1056/nejmoa1407222openalex-snapshot
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
inferredcites →https://doi.org/10.1056/nejmoa1509277openalex-snapshot
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1056/nejmoa1609783openalex-snapshot
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1074/jbc.m003918200openalex-snapshot
CD19-dependent Activation of Akt Kinase in B-lymphocytes
inferredcites →https://doi.org/10.1089/hum.2013.075openalex-snapshot
Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia
inferredcites →https://doi.org/10.1093/jnci/djv439openalex-snapshot
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
inferredcites →https://doi.org/10.1093/oxfordjournals.annonc.a058876openalex-snapshot
Heterogeneity of acute lymphoblastic leukemia in HIV-seropositive patients
inferredcites →https://doi.org/10.1097/mph.0b013e3181bdf211openalex-snapshot
A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1097/ppo.0000000000000035openalex-snapshot
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
inferredcites →https://doi.org/10.1111/bjh.12778openalex-snapshot
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia
inferredcites →https://doi.org/10.1111/bjh.13050openalex-snapshot
Safety and clinical activity of 5‐aza‐2′‐deoxycytidine (decitabine) with or without Hyper‐ CVAD in relapsed/refractory acute lymphocytic leukaemia
inferredcites →https://doi.org/10.1111/bjh.13764openalex-snapshot
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia
inferredcites →https://doi.org/10.1111/j.1365-2141.1976.tb03563.xopenalex-snapshot
Proposals for the Classification of the Acute Leukaemias F rench ‐A merican ‐B ritish (FAB) C o‐operative G roup
inferredcites →https://doi.org/10.1111/j.1365-2141.2009.07744.xopenalex-snapshot
Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia
inferredcites →https://doi.org/10.1111/j.1365-2141.2010.08246.xopenalex-snapshot
Prognostic factors in adult acute lymphoblastic leukaemia
inferredcites →https://doi.org/10.1111/j.1365-2141.2011.08762.xopenalex-snapshot
A phase I study of a combination of anti‐CD19 and anti‐CD22 immunotoxins (Combotox) in adult patients with refractory B‐lineage acute lymphoblastic leukaemia
inferredcites →https://doi.org/10.1126/scitranslmed.3008226openalex-snapshot
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1136/adc.85.4.321openalex-snapshot
Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment
inferredcites →https://doi.org/10.1158/0008-5472.can-08-4884openalex-snapshot
Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1158/1078-0432.ccr-03-0508openalex-snapshot
Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias
inferredcites →https://doi.org/10.1158/1078-0432.ccr-06-2076openalex-snapshot
DNA Methylation as a Therapeutic Target in Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-2980openalex-snapshot
Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-0487openalex-snapshot
Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-3613openalex-snapshot
The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1158/1535-7163.mct-11-0632openalex-snapshot
Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies
inferredcites →https://doi.org/10.1158/1535-7163.mct-12-1182openalex-snapshot
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
inferredcites →https://doi.org/10.1158/1535-7163.mct-16-0233openalex-snapshot
ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
inferredcites →https://doi.org/10.1172/jci45851openalex-snapshot
CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis
inferredcites →https://doi.org/10.1182/blood-2002-03-0704openalex-snapshot
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia---results of the prospective multicenter LALA-94 trial
inferredcites →https://doi.org/10.1182/blood-2003-07-2466openalex-snapshot
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
inferredcites →https://doi.org/10.1182/blood-2003-08-2958openalex-snapshot
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
inferredcites →https://doi.org/10.1182/blood-2004-01-0039openalex-snapshot
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
inferredcites →https://doi.org/10.1182/blood-2005-04-1623openalex-snapshot
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
inferredcites →https://doi.org/10.1182/blood-2005-07-2708openalex-snapshot
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1182/blood-2006-05-018192openalex-snapshot
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
inferredcites →https://doi.org/10.1182/blood-2006-07-037093openalex-snapshot
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials
inferredcites →https://doi.org/10.1182/blood-2006-10-051912openalex-snapshot
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial
inferredcites →https://doi.org/10.1182/blood-2006-11-056754openalex-snapshot
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
inferredcites →https://doi.org/10.1182/blood-2007-02-073528openalex-snapshot
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
inferredcites →https://doi.org/10.1182/blood-2007-10-116186openalex-snapshot
Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study
inferredcites →https://doi.org/10.1182/blood-2008-01-130237openalex-snapshot
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
inferredcites →https://doi.org/10.1182/blood-2008-02-140665openalex-snapshot
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia
inferredcites →https://doi.org/10.1182/blood-2008-03-143115openalex-snapshot
Long-term remission of Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation–etoposide regimen
inferredcites →https://doi.org/10.1182/blood-2008-04-151860openalex-snapshot
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1182/blood-2008-11-185132openalex-snapshot
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
inferredcites →https://doi.org/10.1182/blood-2009-01-199380openalex-snapshot
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993
inferredcites →https://doi.org/10.1182/blood-2009-03-209262openalex-snapshot
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
inferredcites →https://doi.org/10.1182/blood-2009-04-214668openalex-snapshot
DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1182/blood-2011-04-348656openalex-snapshot
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
inferredcites →https://doi.org/10.1182/blood-2011-05-351403openalex-snapshot
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1182/blood-2011-09-377713openalex-snapshot
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
inferredcites →https://doi.org/10.1182/blood-2011-12-389932openalex-snapshot
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1182/blood-2012-03-415448openalex-snapshot
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1182/blood-2012-04-418640openalex-snapshot
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
inferredcites →https://doi.org/10.1182/blood-2012-06-438002openalex-snapshot
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1182/blood-2012-11-466482openalex-snapshot
Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
inferredcites →https://doi.org/10.1182/blood-2013-02-485425openalex-snapshot
Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function
inferredcites →https://doi.org/10.1182/blood-2014-05-552729openalex-snapshot
Current concepts in the diagnosis and management of cytokine release syndrome
inferredcites →https://doi.org/10.1182/blood-2014-09-599894openalex-snapshot
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1182/blood-2014-12-580068openalex-snapshot
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1182/blood-2015-02-580043openalex-snapshot
Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine
inferredcites →https://doi.org/10.1182/blood-2015-03-580027openalex-snapshot
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
inferredcites →https://doi.org/10.1182/blood-2015-08-661702openalex-snapshot
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype
inferredcites →https://doi.org/10.1182/blood-2016-02-701029openalex-snapshot
XLF deficiency results in reduced N-nucleotide addition during V(D)J recombination
inferredcites →https://doi.org/10.1182/blood-2016-03-643544openalex-snapshot
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
inferredcites →https://doi.org/10.1182/blood-2016-03-707562openalex-snapshot
Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1182/blood-2017-02-749101openalex-snapshot
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1182/blood.v104.11.683.683openalex-snapshot
Outcome for Adolescent and Young Adults 16–21 years of age (AYA) with Acute Lymphoblastic Leukemia (ALL) Treated on the Children’ s Cancer Group (CCG) 1961 Study.
inferredcites →https://doi.org/10.1182/blood.v114.22.585.585openalex-snapshot
Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).
inferredcites →https://doi.org/10.1182/blood.v118.21.248.248openalex-snapshot
A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)
inferredcites →https://doi.org/10.1182/blood.v118.21.2592.2592openalex-snapshot
Single-Agent Vincristine Sulfate Liposomes Injection (Marqibo®) Compared to Historical Single-Agent Therapy for Adults with Advanced, Relapsed and/or Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1182/blood.v122.21.2664.2664openalex-snapshot
Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)
inferredcites →https://doi.org/10.1182/blood.v122.21.3900.3900openalex-snapshot
Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14
inferredcites →https://doi.org/10.1182/blood.v122.21.5021.5021openalex-snapshot
Design Of a Phase 1/2 Study Of Moxetumomab Pasudotox In Adult Patients With Relapsed and/Or Refractory Acute Lymphoblastic Leukemia (ALL)
inferredcites →https://doi.org/10.1182/blood.v124.21.2255.2255openalex-snapshot
A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage
inferredcites →https://doi.org/10.1182/blood.v124.21.4491.4491openalex-snapshot
Pre-Clinical Activity of Adct-301, a Novel Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
inferredcites →https://doi.org/10.1182/blood.v124.21.796.796openalex-snapshot
Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403
inferredcites →https://doi.org/10.1182/blood.v126.23.1328.1328openalex-snapshot
A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma
inferredcites →https://doi.org/10.1182/blood.v126.23.1330.1330openalex-snapshot
The JAK Inhibitor Ruxolitinib Is Effective in Treating T Cell Acute Lymphoblastic Leukemia with Gain of Function Mutations in IL-7R Alpha
inferredcites →https://doi.org/10.1182/blood.v126.23.1564.1564openalex-snapshot
Pre-Clinical Development of Adct-402, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies
inferredcites →https://doi.org/10.1182/blood.v126.23.679.679openalex-snapshot
Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)
inferredcites →https://doi.org/10.1182/blood.v126.23.680.680openalex-snapshot
Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
inferredcites →https://doi.org/10.1182/blood.v126.23.681.681openalex-snapshot
Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)
inferredcites →https://doi.org/10.1182/blood.v126.23.796.796openalex-snapshot
Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60
inferredcites →https://doi.org/10.1182/blood.v128.22.2783.2783openalex-snapshot
Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial
inferredcites →https://doi.org/10.1182/blood.v128.22.621.621openalex-snapshot
Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy
inferredcites →https://doi.org/10.1182/blood.v128.22.650.650openalex-snapshot
Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
inferredcites →https://doi.org/10.1182/blood.v64.1.267.267openalex-snapshot
Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B
inferredcites →https://doi.org/10.1182/blood.v85.8.2025.bloodjournal8582025openalex-snapshot
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811
inferredcites →https://doi.org/10.1186/s13148-014-0039-zopenalex-snapshot
DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia
inferredcites →https://doi.org/10.1200/jco.1999.17.12.3835openalex-snapshot
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
inferredcites →https://doi.org/10.1200/jco.2000.18.3.547openalex-snapshot
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
inferredcites →https://doi.org/10.1200/jco.2004.10.050openalex-snapshot
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
inferredcites →https://doi.org/10.1200/jco.2007.15.3528openalex-snapshot
Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study
inferredcites →https://doi.org/10.1200/jco.2008.18.6916openalex-snapshot
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
inferredcites →https://doi.org/10.1200/jco.2008.20.2630openalex-snapshot
Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
inferredcites →https://doi.org/10.1200/jco.2009.25.1900openalex-snapshot
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
inferredcites →https://doi.org/10.1200/jco.2009.26.9456openalex-snapshot
Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1200/jco.2010.28.15_suppl.6506openalex-snapshot
Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL).
inferredcites →https://doi.org/10.1200/jco.2010.32.7270openalex-snapshot
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
inferredcites →https://doi.org/10.1200/jco.2011.39.4403openalex-snapshot
Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
inferredcites →https://doi.org/10.1200/jco.2012.46.2309openalex-snapshot
High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1200/jco.2013.31.15_suppl.10003openalex-snapshot
Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: A Children’s Oncology Group (COG) study (AALL07P1).
inferredcites →https://doi.org/10.1200/jco.2013.52.2425openalex-snapshot
Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial
inferredcites →https://doi.org/10.1200/jco.2016.34.15_suppl.7036openalex-snapshot
Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
inferredcites →https://doi.org/10.1371/journal.pone.0034513openalex-snapshot
DNA Methylation Analysis of Bone Marrow Cells at Diagnosis of Acute Lymphoblastic Leukemia and at Remission
inferredcites →https://doi.org/10.18632/oncotarget.579openalex-snapshot
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels
inferredcites →https://doi.org/10.3109/08880018.2013.777949openalex-snapshot
Acute Lymphoblastic Leukemia in Early Childhood as the Presenting Sign of Ataxia-Telangiectasia Variant
inferredcites →https://doi.org/10.3109/10428190009148847openalex-snapshot
Outcome of Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.3109/10428194.2010.529206openalex-snapshot
Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia
inferredcites →https://doi.org/10.3109/10428194.2015.1110747openalex-snapshot
Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples
inferredcites →https://doi.org/10.3324/haematol.2010.026997openalex-snapshot
The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia
inferredcites →https://doi.org/10.3816/clml.2011.n.007openalex-snapshot
Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy
inferredcites →https://doi.org/10.4049/jimmunol.0900632openalex-snapshot
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
inferredcites →https://doi.org/10.4049/jimmunol.162.12.7088openalex-snapshot
CD19 Amplifies B Lymphocyte Signal Transduction by Regulating Src-Family Protein Tyrosine Kinase Activation
inferredcites →https://doi.org/10.4065/80.11.1517openalex-snapshot
Adult Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.4103/0377-4929.59186openalex-snapshot
High incidence of Epstein Barr virus infection in childhood acute lymphocytic lukemia: A preliminary study
inferredcites →https://doi.org/10.4161/epi.27585openalex-snapshot
Epigenetic deregulation in pediatric acute lymphoblastic leukemia
inferredcites →https://doi.org/10.5003/2151-4194.2.2.259openalex-snapshot
Adult Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.6004/jnccn.2015.0153openalex-snapshot
Acute Lymphoblastic Leukemia, Version 2.2015
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4493917openalex-extracted
Benefits of the Continuous Use of 6-MP/MTX with Pulses of VCR/DEX in Maintenance Therapy for Pediatric Acute Lymphoblastic Leukemia: A Report from South China Children's Leukemia Group
inferred← citeshttps://doi.org/10.1002/1545-5017.70097openalex-snapshot
Changes in Body Composition in Children and Young People Undergoing Treatment for Acute Lymphoblastic Leukemia: A Systematic Review and Meta‐Analysis
inferred← citeshttps://doi.org/10.1002/1878-0261.70053openalex-snapshot
Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1002/9781119819950.ch3openalex-snapshot
Characterizing the Spectrum of Epigenetic Dysregulation Across Lymphoid Malignancies
inferred← citeshttps://doi.org/10.1002/9781394270613.ch11openalex-snapshot
Role of AI in the Prediction of Leukemia and AI‐Driven Predictive Models for Rehabilitation Outcomes in Acute Lymphoblastic Leukemia
inferred← citeshttps://doi.org/10.1002/adtp.202000186openalex-snapshot
A Review of the Current State of Nanomedicines for Targeting and Treatment of Cancers: Achievements and Future Challenges
inferred← citeshttps://doi.org/10.1002/adtp.202100040openalex-snapshot
Engineering Gene Therapy: Advances and Barriers
inferred← citeshttps://doi.org/10.1002/ajh.25620openalex-snapshot
Maintenance therapy in AML: The past, the present and the future
inferred← citeshttps://doi.org/10.1002/ajh.27607openalex-snapshot
The Efficacy of Pediatric‐Inspired Regimens vs. Hyper‐ CVAD in the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Systematic Review and Meta‐Analysis
inferred← citeshttps://doi.org/10.1002/ajh.27637openalex-snapshot
Five‐Year Real‐World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B‐Cell Precursor Acute Lymphoblastic Leukemia
inferred← citeshttps://doi.org/10.1002/ajh.70103openalex-snapshot
Optimizing Asparaginase Treatment for Adolescent and Young Adult ( AYA ) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations
inferred← citeshttps://doi.org/10.1002/ange.202109500openalex-snapshot
A Dual‐Targeting Circular Aptamer Strategy Enables the Recognition of Different Leukemia Cells with Enhanced Binding Ability
inferred← citeshttps://doi.org/10.1002/anie.202109500openalex-snapshot
A Dual‐Targeting Circular Aptamer Strategy Enables the Recognition of Different Leukemia Cells with Enhanced Binding Ability
inferred← citeshttps://doi.org/10.1002/bab.1654openalex-snapshot
Development and characterization of a camelid single‐domain antibody directed to human CD22 biomarker
inferred← citeshttps://doi.org/10.1002/btpr.2957openalex-snapshot
Atomistic probing of aptameric binding of CD19 outer membrane domain reveals an “aptamer walking” mechanism
inferred← citeshttps://doi.org/10.1002/cam4.1328openalex-snapshot
Effectiveness of modified hyper‐ CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience
inferred← citeshttps://doi.org/10.1002/cam4.6495openalex-snapshot
Clinical characteristics and risk factors of acute lymphoblastic leukemia in children with severe infection during maintenance treatment
inferred← citeshttps://doi.org/10.1002/cbdv.202503194openalex-snapshot
Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia
inferred← citeshttps://doi.org/10.1002/cbf.3687openalex-snapshot
Telomerase‐based therapies in haematological malignancies
inferred← citeshttps://doi.org/10.1002/cbin.11779openalex-snapshot
Inhibition of Skp2 enhances doxorubicin‐induced cell death in B cell precursor acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1002/cbin.11865openalex-snapshot
The altered expression of homing factors in CD34+ hematopoietic stem cells following G‐CSF injection and its effects on transplantation quality in ALL patients
inferred← citeshttps://doi.org/10.1002/ccr3.73111openalex-snapshot
Acute Lymphoblastic Leukemia Presenting With Severe Acute Kidney Injury Requiring Hemodialysis due to Kidney Infiltration: A Case Report
inferred← citeshttps://doi.org/10.1002/cncr.35505openalex-snapshot
Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions
inferred← citeshttps://doi.org/10.1002/cnr2.1290openalex-snapshot
Recurrent genetic abnormalities detected by FISH in adult B ALL and association with hematological parameters
inferred← citeshttps://doi.org/10.1002/cnr2.1702openalex-snapshot
Survival estimates of childhood malignancies treated at the Mexican telethon pediatric oncology hospital
inferred← citeshttps://doi.org/10.1002/cnr2.70351openalex-snapshot
Update Prognostic Potency of Vascular Endothelial Growth Factor‐A in the Acute Lymphoblastic Leukemia Landscape: A Meta‐Analysis
inferred← citeshttps://doi.org/10.1002/cyto.a.24821openalex-snapshot
Label‐free cell detection of acute leukemia using ghost cytometry
inferred← citeshttps://doi.org/10.1002/cyto.b.22043openalex-snapshot
Correlation between a 10‐color flow cytometric measurable residual disease ( MRD ) analysis and molecular MRD in adult B‐acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1002/elan.202200456openalex-snapshot
Electrochemical detection of asparaginase antibodies using bifunctionalized carbon interfaces
inferred← citeshttps://doi.org/10.1002/fsn3.70788openalex-snapshot
Comparative Analysis of Breastfeeding and Infant Formulas: Short‐ and Long‐Term Impacts on Infant Nutrition and Health
inferred← citeshttps://doi.org/10.1002/hon.2936openalex-snapshot
Global burden and attributable risk factors of acute lymphoblastic leukemia in 204 countries and territories in 1990–2019: Estimation based on Global Burden of Disease Study 2019
inferred← citeshttps://doi.org/10.1002/hon.3029openalex-snapshot
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment
inferred← citeshttps://doi.org/10.1002/hon.3114openalex-snapshot
Outcome and molecular measurable residual disease monitoring in adult B‐cell acute lymphoblastic leukemia patients with MEF2D fusions
inferred← citeshttps://doi.org/10.1002/hon.70108openalex-snapshot
A Comparative Study of Bone Marrow and Central Nervous System Microenvironment Models to Improve In Vitro Studies of Acute Lymphoblastic Leukemia
inferred← citeshttps://doi.org/10.1002/hsr2.72497openalex-snapshot
CRISPR Genome Editing and the Future of Leukaemia Immunotherapy
inferred← citeshttps://doi.org/10.1002/ijc.33527openalex-snapshot
Deleterious point mutations in T‐cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis
inferred← citeshttps://doi.org/10.1002/ima.70189openalex-snapshot
MHAOSL ‐Net: A Global Context‐Aware Attention Free Transformer Network With Orthogonal SoftMax Layer to Detect Subtypes of Acute Lymphoblastic Leukemia
inferred← citeshttps://doi.org/10.1002/jat.4398openalex-snapshot
Interaction between environmental pollutants and cancer drug efficacy: Bisphenol A, Bisphenol A diglycidyl ether and Perfluorooctanoic acid reduce vincristine cytotoxicity in acute lymphoblastic leukemia cells
inferred← citeshttps://doi.org/10.1002/jbt.70315openalex-snapshot
Advances in Exosome Research: Multifaceted Roles in Myeloid Leukemia Progression and Therapy
inferred← citeshttps://doi.org/10.1002/jcp.28903openalex-snapshot
Autophagy regulation and its role in normal and malignant hematopoiesis
inferred← citeshttps://doi.org/10.1002/jcp.70000openalex-snapshot
Reprogramming of Fatty Acid Metabolism in Acute Leukemia
inferred← citeshttps://doi.org/10.1002/jctb.6933openalex-snapshot
Engineered asparaginase from Erwinia chrysanthemi enhances asparagine hydrolase activity and diminishes enzyme immunoreactivity ‐ a new promise to treat acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1002/jgm.3044openalex-snapshot
MIF‐173G/C (rs755622) polymorphism as a risk factor for acute lymphoblastic leukemia development in children
inferred← citeshttps://doi.org/10.1002/jha2.70172openalex-snapshot
Socioeconomic Disparities in Allogeneic Transplant Access Within a Publicly Funded Healthcare System
inferred← citeshttps://doi.org/10.1002/med.21575openalex-snapshot
ETS transcription factors as emerging drug targets in cancer
inferred← citeshttps://doi.org/10.1002/pbc.29651openalex-snapshot
Malnutrition in a child with T‐cell ALL leading to superior mesenteric artery syndrome and Wernicke's encephalopathy
inferred← citeshttps://doi.org/10.1002/pbc.30138openalex-snapshot
The prognostic significance of hematogones in childhood B‐cell acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1002/pbc.31738openalex-snapshot
Hypersensitivity to Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia and Management With Desensitization
inferred← citeshttps://doi.org/10.1002/sstr.202100096openalex-snapshot
Extracellular Vesicles for the Diagnosis of Cancers
inferred← citeshttps://doi.org/10.1007/978-1-0716-0759-6_14openalex-snapshot
Chimeric Antigen Receptor (CAR) T Cell Therapy for Cancer. Challenges and Opportunities: An Overview
inferred← citeshttps://doi.org/10.1007/978-3-030-02278-5_71openalex-snapshot
Acute Lymphoblastic Leukemia in Adults
inferred← citeshttps://doi.org/10.1007/978-3-030-53633-6_18openalex-snapshot
Management of Relapsed and Refractory ALL
inferred← citeshttps://doi.org/10.1007/978-3-030-67123-5_36openalex-snapshot
Hyperleukocytosis and Leukostasis
inferred← citeshttps://doi.org/10.1007/978-3-030-80558-6_2openalex-snapshot
Prostate Apoptosis Response-4 in Inflammation
inferred← citeshttps://doi.org/10.1007/978-3-030-80558-6_9openalex-snapshot
The Par-4 Tumor Suppressor Protein in TCL1-Induced Leukemogenesis
inferred← citeshttps://doi.org/10.1007/978-3-030-85147-7_5openalex-snapshot
Treatment of Adult B- and T-Cell Acute Lymphoblastic Leukemia: An Overview of Current Treatments and Novel Advances
inferred← citeshttps://doi.org/10.1007/978-3-030-91699-2_20openalex-snapshot
Quaternion-Valued Convolutional Neural Network Applied for Acute Lymphoblastic Leukemia Diagnosis
inferred← citeshttps://doi.org/10.1007/978-3-030-99708-3_7openalex-snapshot
Hyaluronan in the Extracellular Matrix of Hematological and Solid Tumors. Its Biological Effects
inferred← citeshttps://doi.org/10.1007/978-3-031-32046-0_67-1openalex-snapshot
Quality of Life Domains in Acute Leukaemia
inferred← citeshttps://doi.org/10.1007/978-3-031-44080-9_72openalex-snapshot
Acute Lymphoblastic Leukemia in Adults
inferred← citeshttps://doi.org/10.1007/978-3-031-73363-5_67openalex-snapshot
Quality of Life Domains in Acute Leukemia
inferred← citeshttps://doi.org/10.1007/978-3-031-82931-4_16openalex-snapshot
Comprehensive Evaluation of GAN Architectures for Acute Lymphoblastic Leukemia Classification
inferred← citeshttps://doi.org/10.1007/978-3-031-88695-9_5openalex-snapshot
CAR-T-Cell Therapy: Success and Advancements in the Treatment of Hematological Malignancies
inferred← citeshttps://doi.org/10.1007/978-3-032-12705-1_12openalex-snapshot
Phenotypic Signature of Leukemic Stem Cells and Their Signaling Pathways for Potential Targeting Strategies
inferred← citeshttps://doi.org/10.1007/978-3-032-13803-3_28openalex-snapshot
Acute Lymphoblastic Leukemia Detection Using Machine Learning
inferred← citeshttps://doi.org/10.1007/978-3-032-19529-6_13openalex-snapshot
Blood Cell Cancer Prediction Using Lightning CNN with XAI Interpretability (LIME and SHAP)
inferred← citeshttps://doi.org/10.1007/978-3-319-74588-6_94openalex-snapshot
Hyperleukocytosis in Cancer Patients
inferred← citeshttps://doi.org/10.1007/978-3-319-74698-2_94-1openalex-snapshot
Hyperleukocytosis in Cancer Patients
inferred← citeshttps://doi.org/10.1007/978-3-319-74698-2_94-2openalex-snapshot
Malignant Hematological Diseases: Hyperleukocytosis
inferred← citeshttps://doi.org/10.1007/978-981-10-8417-1_10openalex-snapshot
Anticancerous Plant Compounds Affecting the Power House of Cancerous Cells: A Possible Herbal Mitocan
inferred← citeshttps://doi.org/10.1007/978-981-13-7713-6_11openalex-snapshot
Molecular Biology of B- and T-ALL
inferred← citeshttps://doi.org/10.1007/978-981-16-1395-1_40openalex-snapshot
Decision Support Technique for Prediction of Acute Lymphoblastic Leukemia Subtypes Based on Artificial Neural Network and Adaptive Neuro-Fuzzy Inference System
inferred← citeshttps://doi.org/10.1007/978-981-16-9186-7_7openalex-snapshot
Role of Circulating MicroRNAs in Prognosis and Diagnosis of Cancers
inferred← citeshttps://doi.org/10.1007/978-981-95-0681-1_5openalex-snapshot
An Efficient Ensemble Strategy for Acute Lymphoblastic Leukemia Classification
inferred← citeshttps://doi.org/10.1007/978-981-95-3628-3_5openalex-snapshot
Clinical Success of CAR T Cells in Hematologic Cancers: Lessons from Leukemia and Lymphoma
inferred← citeshttps://doi.org/10.1007/978-981-97-0146-9_8openalex-snapshot
Combination Drug Strategies for Targeting Specific Biochemical Pathways for Superior Therapeutic Potency
inferred← citeshttps://doi.org/10.1007/978-981-99-3810-0_19openalex-snapshot
Genomic Landscape of Acute Lymphoblastic Leukemia (ALL): Insights to Leukemogenesis, Prognostications, and Treatment
inferred← citeshttps://doi.org/10.1007/978-981-99-3810-0_24openalex-snapshot
Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia
inferred← citeshttps://doi.org/10.1007/978-981-99-3810-0_26openalex-snapshot
In the Pipeline—Emerging Therapy for ALL
inferred← citeshttps://doi.org/10.1007/s00005-020-00599-xopenalex-snapshot
The Application of CAR-T Cells in Haematological Malignancies
inferred← citeshttps://doi.org/10.1007/s00011-022-01646-3openalex-snapshot
The inflammasomes: crosstalk between innate immunity and hematology
inferred← citeshttps://doi.org/10.1007/s00044-020-02563-yopenalex-snapshot
Inducing apoptosis through upregulation of p53: structure–activity exploration of anthraquinone analogs
inferred← citeshttps://doi.org/10.1007/s00262-020-02484-0openalex-snapshot
New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia
inferred← citeshttps://doi.org/10.1007/s00262-020-02614-8openalex-snapshot
Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions
inferred← citeshttps://doi.org/10.1007/s00277-020-04277-yopenalex-snapshot
Association of three factors (ABCB1 gene expression, steroid response, early response at day + 8) on the response to induction in patients with acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1007/s00277-024-05764-2openalex-snapshot
Specificity protein 1/3 regulate T-cell acute lymphoblastic leukemia cell proliferation and apoptosis through β-catenin by acting as targets of miR-495-3p
inferred← citeshttps://doi.org/10.1007/s00277-024-05821-wopenalex-snapshot
Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities
inferred← citeshttps://doi.org/10.1007/s00277-025-06597-3openalex-snapshot
T-cell acute lymphoblastic leukemia: therapeutic outcomes in adolescents and young adults
inferred← citeshttps://doi.org/10.1007/s00277-026-06838-zopenalex-snapshot
Real-world outcomes of inotuzumab ozogamicin treatment for adult relapsed or refractory acute lymphoblastic leukemia: a result from Korea post-marketing surveillance
inferred← citeshttps://doi.org/10.1007/s00277-026-06845-0openalex-snapshot
Identification of the Philadelphia-like subgroup in Turkish pediatric patients with acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1007/s00431-025-06039-2openalex-snapshot
Vincristine-induced ptosis in pediatric patients: a systematic review and practice recommendations
inferred← citeshttps://doi.org/10.1007/s00432-023-04974-xopenalex-snapshot
Association of CDKN2A/B mutations, PD-1, and PD-L1 with the risk of acute lymphoblastic leukemia in children
inferred← citeshttps://doi.org/10.1007/s00432-024-05692-8openalex-snapshot
Chemotherapy-initiated cysteine-rich protein 61 decreases acute B-lymphoblastic leukemia chemosensitivity
inferred← citeshttps://doi.org/10.1007/s00432-025-06247-1openalex-snapshot
A cross-sectional analysis of the global burden of childhood leukemia from 1990 to 2021
inferred← citeshttps://doi.org/10.1007/s00520-018-4583-5openalex-snapshot
Pain in patients with newly diagnosed or relapsed acute leukemia
inferred← citeshttps://doi.org/10.1007/s00520-019-05047-xopenalex-snapshot
Is heart rate variability a valuable method to investigate cardiac autonomic dysfunction in subjects with leukemia? A systematic review to evaluate its importance in clinical practice
inferred← citeshttps://doi.org/10.1007/s00520-020-05629-0openalex-snapshot
Impact of respiratory physical therapy on heart rate autonomic control in children with leukemia
inferred← citeshttps://doi.org/10.1007/s00520-020-05819-wopenalex-snapshot
Patient ambassador support in newly diagnosed patients with acute leukemia during treatment: a feasibility study
inferred← citeshttps://doi.org/10.1007/s00520-025-09250-xopenalex-snapshot
Effect of adaptive variable-resistance training on chemotherapy-induced sarcopenia, fatigue, and functional restriction in pediatric survivors of acute lymphoblastic leukemia: a prospective randomized controlled trial
inferred← citeshttps://doi.org/10.1007/s00520-025-09365-1openalex-snapshot
Walking inability in children during early treatment of acute lymphoblastic leukaemia: incidence and risk factors
inferred← citeshttps://doi.org/10.1007/s00792-025-01411-4openalex-snapshot
Antitumor potential of glutaminase- and urease-free L-asparaginase from Antarctic fungus Mortierella turficola
inferred← citeshttps://doi.org/10.1007/s10067-022-06459-7openalex-snapshot
Osteoarticular manifestation of acute lymphoblastic leukemia in adults: a literature review
inferred← citeshttps://doi.org/10.1007/s10198-020-01207-7openalex-snapshot
Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan’s health care system
inferred← citeshttps://doi.org/10.1007/s10238-023-01000-9openalex-snapshot
Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia
inferred← citeshttps://doi.org/10.1007/s10238-025-01823-8openalex-snapshot
The expression of CD109 in B-cell acute lymphoblastic leukemia and its potential as a promising marker for minimal residual disease (MRD) detection
inferred← citeshttps://doi.org/10.1007/s10238-026-02273-6openalex-snapshot
Prognostic factor analysis of CD19 CAR-T therapy followed by hematopoietic stem cell transplantation in relapsed/refractory B-ALL
inferred← citeshttps://doi.org/10.1007/s10544-020-00503-6openalex-snapshot
Microfluidic Chip based direct triple antibody immunoassay for monitoring patient comparative response to leukemia treatment
inferred← citeshttps://doi.org/10.1007/s10555-017-9699-4openalex-snapshot
(Immuno)proteasomes as therapeutic target in acute leukemia
inferred← citeshttps://doi.org/10.1007/s10555-024-10203-9openalex-snapshot
Molecular and cellular mechanisms of chemoresistance in paediatric pre–B cell acute lymphoblastic leukaemia
inferred← citeshttps://doi.org/10.1007/s10565-021-09640-xopenalex-snapshot
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
inferred← citeshttps://doi.org/10.1007/s10637-021-01066-wopenalex-snapshot
AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis
inferred← citeshttps://doi.org/10.1007/s10637-024-01435-1openalex-snapshot
Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1007/s11010-024-05198-4openalex-snapshot
GNA15 induces drug resistance in B cell acute lymphoblastic leukemia by promoting fatty acid oxidation via activation of the AMPK pathway
inferred← citeshttps://doi.org/10.1007/s11033-019-04649-2openalex-snapshot
Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature
inferred← citeshttps://doi.org/10.1007/s11033-019-04703-zopenalex-snapshot
Evaluating the expression level of Survivin gene in different groups of B-cell acute lymphoblastic leukemia patients of Iran
inferred← citeshttps://doi.org/10.1007/s11033-021-06572-xopenalex-snapshot
Britannin, a sesquiterpene lactone induces ROS-dependent apoptosis in NALM-6, REH, and JURKAT cell lines and produces a synergistic effect with vincristine
inferred← citeshttps://doi.org/10.1007/s11033-022-08016-6openalex-snapshot
Expression analysis of circulating miR-22, miR-122, miR-217 and miR-367 as promising biomarkers of acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1007/s11033-024-10200-9openalex-snapshot
Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53
inferred← citeshttps://doi.org/10.1007/s11033-025-10674-1openalex-snapshot
An overview on in-vivo generation of CAR-T cells using CRISPR-loaded functionalized nanocarriers for treating B-cell lineage acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1007/s11033-026-12127-9openalex-snapshot
Peripheral blood mRNA expression of IL37, IL1F10, and C17orf99 genes is altered in patients with B-acute lymphoblastic leukemia: a case-control study
inferred← citeshttps://doi.org/10.1007/s11042-022-12108-7openalex-snapshot
A survey on automated detection and classification of acute leukemia and WBCs in microscopic blood cells
inferred← citeshttps://doi.org/10.1007/s11042-023-16191-2openalex-snapshot
DeepLeukNet—A CNN based microscopy adaptation model for acute lymphoblastic leukemia classification
inferred← citeshttps://doi.org/10.1007/s11042-024-19422-2openalex-snapshot
Deep learning enabled fractional fire hawk’s hunter optimization for leukemia segmentation and detection using blood smear image
inferred← citeshttps://doi.org/10.1007/s11042-024-20312-wopenalex-snapshot
A deep transfer learning based approaches for the detection and classification of acute lymphocytic leukemia using microscopic images
inferred← citeshttps://doi.org/10.1007/s11224-026-02880-9openalex-snapshot
Structural characterization and cytotoxicity of novel phthalazine–sulfonamides
inferred← citeshttps://doi.org/10.1007/s11306-020-01710-1openalex-snapshot
Cationic amphiphilic drugs induce elevation in lysoglycerophospholipid levels and cell death in leukemia cells
inferred← citeshttps://doi.org/10.1007/s11306-021-01814-2openalex-snapshot
Impact of acute lymphoblastic leukemia induction therapy: findings from metabolomics on non-fasted plasma samples from a biorepository
inferred← citeshttps://doi.org/10.1007/s11523-025-01129-5openalex-snapshot
CIBMTR Registry Data on Inotuzumab Ozogamicin Treatment in Patients with ALL Who Proceeded to Hematopoietic Stem Cell Transplant—A Podcast
inferred← citeshttps://doi.org/10.1007/s11756-022-01072-0openalex-snapshot
Bioprospection of l-asparaginase producing microorganisms and cloning of the l-asparaginase type II gene from a Pseudomonas putida species group isolate
inferred← citeshttps://doi.org/10.1007/s11845-025-04065-5openalex-snapshot
Exploring the impact of IKZF1 and its targeting microRNAs in the pathogenesis of acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1007/s11864-024-01237-wopenalex-snapshot
Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL)
inferred← citeshttps://doi.org/10.1007/s11899-018-0456-8openalex-snapshot
Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
inferred← citeshttps://doi.org/10.1007/s11899-020-00591-4openalex-snapshot
Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia
inferred← citeshttps://doi.org/10.1007/s11899-021-00641-5openalex-snapshot
Application of Next-Generation Sequencing-Based Mutational Profiling in Acute Lymphoblastic Leukemia
inferred← citeshttps://doi.org/10.1007/s11899-022-00661-9openalex-snapshot
Targeting Apoptosis in ALL
inferred← citeshttps://doi.org/10.1007/s12011-023-03958-9openalex-snapshot
Boric Acid Affects Cell Proliferation, Apoptosis, and Oxidative Stress in ALL Cells
inferred← citeshttps://doi.org/10.1007/s12012-021-09665-yopenalex-snapshot
Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways
inferred← citeshttps://doi.org/10.1007/s12013-025-01750-1openalex-snapshot
KPT-330, A New Candidate Drug for Targeting NOTCH1 Overexpression in T-cell Acute Lymphoblastic Leukemia, An In Vitro and Silico Study
inferred← citeshttps://doi.org/10.1007/s12015-020-10008-7openalex-snapshot
Treatment of CML-transformed B Cell Acute Lymphoblastic Leukemia (B-ALL) in Adults with Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy
inferred← citeshttps://doi.org/10.1007/s12026-024-09577-3openalex-snapshot
The effects of bone marrow humoral components of B-cell acute lymphoblastic leukemia patients on natural killer cell suppression
inferred← citeshttps://doi.org/10.1007/s12026-025-09712-8openalex-snapshot
Hypermethylation of lysosomal-associated genes LAMP1 and LAMP2 compromises lysosome function in patients with acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1007/s12032-022-01709-9openalex-snapshot
S100A8 inhibition in leukemic lymphoblasts induces sensitivity to chemotherapy and inhibition of disease relapse
inferred← citeshttps://doi.org/10.1007/s12032-022-01813-wopenalex-snapshot
Panobinostat (LBH589) increase survival in adult xenografic model of acute lymphoblastic leukemia with t(4;11) but promotes antagonistic effects in combination with MTX and 6MP
inferred← citeshttps://doi.org/10.1007/s12032-024-02485-4openalex-snapshot
The impact of Trifolium pratense extract on apoptosis and autophagy in NALM-6 cells: implications for B-ALL intervention
inferred← citeshttps://doi.org/10.1007/s12032-025-02924-wopenalex-snapshot
CXCR4-targeted theranostics in acute leukemia: disrupting leukemic cell-microenvironment interactions with pentixafor and pentixather
inferred← citeshttps://doi.org/10.1007/s12033-020-00296-2openalex-snapshot
Oncological Ligand-Target Binding Systems and Developmental Approaches for Cancer Theranostics
inferred← citeshttps://doi.org/10.1007/s12041-024-01470-0openalex-snapshot
Foetal haemoglobin elevation, unfavourable prognosis, and protective role of genetic variants HBG2 rs7482144, HBS1L-MYB rs9399137 and BCL11A rs4671393 in children with ALL
inferred← citeshttps://doi.org/10.1007/s12098-023-04745-zopenalex-snapshot
Relapsed/Refractory T- Acute Lymphoblastic Leukemia — Current Options and Future Directions
inferred← citeshttps://doi.org/10.1007/s12185-019-02678-yopenalex-snapshot
Outcomes of adult acute lymphoblastic leukemia in the era of pediatric-inspired regimens: a single-center experience
inferred← citeshttps://doi.org/10.1007/s12185-022-03368-yopenalex-snapshot
Propensity score matching/reweighting analysis comparing autologous and allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1007/s12247-024-09836-8openalex-snapshot
Development and Evaluation of Stable Long Circulating Decitabine-loaded Copolymeric Nanoparticles: Harnessing QbD Approach and Lyophilization Technique
inferred← citeshttps://doi.org/10.1007/s12288-019-01123-8openalex-snapshot
Evaluation of Cytogenetic Abnormalities in Patients with Acute Lymphoblastic Leukemia
inferred← citeshttps://doi.org/10.1007/s12288-019-01214-6openalex-snapshot
The Expression of P53, MDM2, c-myc, and P14ARF Genes in Newly Diagnosed Acute Lymphoblastic Leukemia Patients
inferred← citeshttps://doi.org/10.1007/s12288-020-01295-8openalex-snapshot
Recent Advances in Molecular Diagnosis and Prognosis of Childhood B Cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
inferred← citeshttps://doi.org/10.1007/s12288-020-01345-1openalex-snapshot
The Outcome of Acute Lymphoblastic Leukemia in 109 Adult Iraqi Patients
inferred← citeshttps://doi.org/10.1007/s12288-024-01832-9openalex-snapshot
A Prospective Observational Study of the Prognostic Role of Procalcitonin Compared with High Sensitivity C Reactive Protein in Patients ≥ 15Years of Age with Acute Lymphoblastic Leukemia/Lymphoma with Febrile Neutropenia
inferred← citeshttps://doi.org/10.1007/s12288-026-02382-yopenalex-snapshot
The Effect of L-asparaginase Level Monitoring on Minimal Residual Disease of Childhood Acute Lymphoblastic Leukaemia: A Study from Eastern India
inferred← citeshttps://doi.org/10.1007/s12308-025-00640-yopenalex-snapshot
CD5-positive B-cell acute lymphoblastic leukemia/lymphoma with MEF2D::BCL9 mimicking aggressive mature B-cell lymphoma: a case report of a newly described entity and potential diagnostic pitfall
inferred← citeshttps://doi.org/10.1007/s12325-019-00991-wopenalex-snapshot
Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
inferred← citeshttps://doi.org/10.1007/s12325-019-01099-xopenalex-snapshot
Clinicians’ Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study
inferred← citeshttps://doi.org/10.1007/s12325-019-0873-7openalex-snapshot
Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
inferred← citeshttps://doi.org/10.1007/s12672-024-01245-0openalex-snapshot
Glutamine and leukemia research: progress and clinical prospects
inferred← citeshttps://doi.org/10.1007/s12672-025-04102-wopenalex-snapshot
Charting the landscape and evolution of research on cell death in acute lymphoblastic leukemia: a comprehensive bibliometric analysis (1990–2024)
inferred← citeshttps://doi.org/10.1007/s12672-026-04593-1openalex-snapshot
The combination therapy with venetoclax in therapeutic strategy of acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1007/s13205-024-03935-6openalex-snapshot
Double Philadelphia chromosome: a rare and sole abnormality in pediatric B-acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1007/s13205-026-04949-yopenalex-snapshot
Association of wheatgrass (Triticum aestivum) preparation in regulation of antigen presentation through the immunomodulation and epigenetic modification in acute leukemia
inferred← citeshttps://doi.org/10.1007/s13318-021-00726-9openalex-snapshot
Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights
inferred← citeshttps://doi.org/10.1007/s13353-019-00524-9openalex-snapshot
The correction of ETV6/RUNX1 translocation in acute lymphocytic leukemia cells: a new gene targeting system by homologous recombination mechanism
inferred← citeshttps://doi.org/10.1007/s13402-020-00551-3openalex-snapshot
Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1007/s15015-018-3601-2openalex-snapshot
Therapiestrategien bei Erwachsenen mit akuter lymphatischer Leukämie
inferred← citeshttps://doi.org/10.1007/s40142-018-0147-8openalex-snapshot
Significance of Cytogenetics in Leukemia Diagnostics
inferred← citeshttps://doi.org/10.1007/s40262-018-00734-0openalex-snapshot
The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children’s Oncology Group
inferred← citeshttps://doi.org/10.1007/s40273-019-00779-4openalex-snapshot
The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
inferred← citeshttps://doi.org/10.1007/s40273-019-00812-6openalex-snapshot
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
inferred← citeshttps://doi.org/10.1007/s40368-021-00679-2openalex-snapshot
Salivary parameters and their correlation with neutrophil counts in children with acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1007/s40487-025-00336-4openalex-snapshot
Understanding Patients’ Experiences in Newly Diagnosed Adult B Cell Acute Lymphoblastic Leukemia: Qualitative Interviews to Develop a Patient-Centric Conceptual Model
inferred← citeshttps://doi.org/10.1007/s40620-025-02381-8openalex-snapshot
Deceased donor kidney transplantation in candidates with pre-transplant hematological malignancies: a literature review and recipient allocation proposal in Singapore
inferred← citeshttps://doi.org/10.1007/s42979-023-02414-8openalex-snapshot
Geometry-Based Counting and Classification of WBCs for Analysis of Leukocyte Disorders
inferred← citeshttps://doi.org/10.1007/s43674-024-00078-2openalex-snapshot
Non-linear machine learning with sample perturbation augments leukemia relapse prognostics from single-cell proteomics measurements
inferred← citeshttps://doi.org/10.1007/s44313-024-00007-9openalex-snapshot
Impact of CYP1A1 variants on the risk of acute lymphoblastic leukemia: evidence from an updated meta-analysis
inferred← citeshttps://doi.org/10.1007/s44313-026-00175-wopenalex-snapshot
High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy
inferred← citeshttps://doi.org/10.1007/s44372-024-00009-yopenalex-snapshot
Effect of abiotic and biotic elicitors on vincristine accumulation in endosperm derived in vitro cultures in Catharanthus roseous (L.) G. Don
inferred← citeshttps://doi.org/10.1016/b978-0-12-813814-4.00031-6openalex-snapshot
Hormone Effects on Tumors
inferred← citeshttps://doi.org/10.1016/b978-0-12-817962-8.00020-2openalex-snapshot
Biological and molecular markers in childhood malignancies
inferred← citeshttps://doi.org/10.1016/b978-0-12-820007-0.00035-0openalex-snapshot
Translation of gene therapies
inferred← citeshttps://doi.org/10.1016/b978-0-323-56738-1.00009-9openalex-snapshot
Precursor Lymphoid Neoplasms
inferred← citeshttps://doi.org/10.1016/b978-0-323-69538-1.00029-xopenalex-snapshot
Myeloma and Leukemia
inferred← citeshttps://doi.org/10.1016/b978-0-443-15717-2.00017-2openalex-snapshot
Molecular Implications of BCR-ABL1 in Hematological Malignancies
inferred← citeshttps://doi.org/10.1016/b978-0-443-44000-7.00007-3openalex-snapshot
Leveraging artificial intelligence and machine learning for leukemia cancer management
inferred← citeshttps://doi.org/10.1016/bs.vh.2025.01.001openalex-snapshot
B lymphoproliferative diseases: Effective treatment, inhibited progression, and potential cures through isoform-specific targeting of the prolactin receptor
inferred← citeshttps://doi.org/10.1016/j.ab.2024.115619openalex-snapshot
Identification of potential inhibitors for drug resistance in acute lymphoblastic leukemia through differentially expressed gene analysis and in silico screening
inferred← citeshttps://doi.org/10.1016/j.aca.2020.02.060openalex-snapshot
Different liposome patterns to detection of acute leukemia based on electrochemical cell sensor
inferred← citeshttps://doi.org/10.1016/j.acpath.2022.100045openalex-snapshot
Educational Case: Diagnostic studies for B-cell acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1016/j.addr.2019.04.003openalex-snapshot
Tissue engineered models of healthy and malignant human bone marrow
inferred← citeshttps://doi.org/10.1016/j.ahj.2023.07.001openalex-snapshot
Importance of familial predisposition to heart failure to the risk of anthracycline-related cardiotoxicity: A nationwide study
showing the first 200 of 1274 · page through all 1274
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.